• 1
    Drazen JM, Arm JP, Austen KF. Sorting out the cytokines of asthma. J Exp Med 1996; 183: 15.
  • 2
    Broide DH, Firestein GS. Endobronchial allergen challenge in asthma. Demonstration of cellular source of granulocyte macrophage colony-stimulating factor by in situ hybridization. J Clin Invest 1991; 88: 104853.
  • 3
    Robinson DS, Hamid Q, Ying S, Tsicopoulos A, Barkans J, Bentley AM, Corrigan C, Durham SR, Kay AB. Predominant Th2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med 1992; 326: 298304.
  • 4
    Woolley KL, Adelroth E, Woolley MJ, Ellis R, Jordana M, O'Byrne PM. Granulocyte-macrophage colony-stimulating factor, eosinophils and eosinophil-cationic protein in subjects with and without mild, stable, atopic asthma. Eur Respir J 1994; 7: 157684.
  • 5
    Heinig HA, Boulet LP, Croonenborghs L, Möllers MJ. The effect of high-dose fluticasone proprionate and budesonide on lung function and asthma exacerbations in patients with severe asthma. Respir Med 1999; 93: 61320.
  • 6
    Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ, Pauwels RA, Pedersen SE. for the GOAL Investigators Group. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 2004; 170: 83644.
  • 7
    Green RH, Brightling CE, Bradding P. The reclassification of asthma based on subphenotypes. Curr Opin Allergy Clin Immunol 2007; 7: 4350.
  • 8
    Haldar P, Pavord ID, Shaw DE, Berry MA, Thomas M, Brightling CE. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008; 178: 21824.
  • 9
    Bradding PB, Green RH. Subclinical phenotypes of asthma. Curr Opin Allergy Clin Immunol 2010; 10: 549.
  • 10
    Woodruff PG, Modrek B, Choy DF, Jia G, Abbas AR, Ellwanger A, Koth LL, Arron JR, Fahy JV. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med 2009; 180: 38895.
  • 11
    LaPorte SL, Juo ZS, Vaclavikova J, Colf LA, Qi X, Heller NM, Keegan AD, Garcia KC. Molecular and structural basis of cytokine receptor pleiotropy in the interleukin-4/13 system. Cell 2008; 132: 25972.
  • 12
    Hershey GK. IL-13 receptors and signaling pathways: an evolving web. J Allergy Clin Immunol 2003; 111: 67790.
  • 13
    Fichtner-Feigl S, Strober W, Kawakami K, Puri RK, Kitani A. IL-13 signaling through IL-13α2 receptor is involved in induction of TGF-β1 production and fibrosis. Nat Med 2006; 12: 99106.
  • 14
    Wills-Karp M, Luyimbazi J, Xu X, Schofield B, Neben TY, Karp CL, Donaldson DD. Interleukin-13: central mediator in allergic asthma. Science 1998; 282: 225861.
  • 15
    Grunig G, Warnock M, Wakil AE, Venkayya R, Brombacher F, Rennick DM, Sheppard D, Mohrs M, Donaldson DD, Locksley RM, Corry DB. Requirement for IL-13 independently of IL-4 in experimental asthma. Science 1998; 282: 22613.
  • 16
    Lupardus PJ, Birnbaum ME, Garcia KC. Molecular basis for shared cytokine recognition revealed in the structure of an unusually high affinity complex between IL-13 and IL-13 Rα2. Structure 2010; 18: 33242.
  • 17
    Erin EM, Zacharasiewicz AS, Nicholson GC, Tan AJ, Higgins LA, Williams TJ, Murdoch RD, Durham SR, Barnes PJ, Hansel TT. Topical corticosteroid inhibits interleukin-4, -5 and -13 in nasal secretions following allergen challenge. Clin Exp Allergy 2005; 35: 160814.
  • 18
    Dreskin SC, Dale SN, Foster SM, Martin D, Buchmeier A, Nelson HS. Measurement of changes in mRNA for IL-5 in non-invasive scrapings of nasal epithelium taken from patients undergoing nasal allergen challenge. J Immunol Methods 2002; 268: 18995.
  • 19
    Nye L, Merrett TG, Landon J, White RJ. A detailed investigation of circulating IgE levels in a normal population. Clin Allergy 1975; 5: 1324.
  • 20
    Wittig HJ, Belloit J, De Fillippi I, Royal G. Age-related serum IgE levels in healthy subjects and in patients with allergic disease. J Allergy Clin Immunol 1980; 66: 30513.
  • 21
    Wills-Karp M. Interleukin-13 in asthma pathogenesis. Immunol Rev 2004; 202: 17590.
  • 22
    Zhu Z, Homer RJ, Wang Z, Chen Q, Geba GP, Wang J. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest 1999; 103: 77988.
  • 23
    Yang G, Volk A, Petley T, Emmell E, Giles-Komar J, Shang X, Li J, Das AM, Shealy D, Griswold DE, Li L. Anti-IL-13 monoclonal antibody inhibits airway hyperresponsiveness, inflammation and airway remodeling. Cytokine 2004; 28: 22432.
  • 24
    Fulkerson PC, Fischetti CA, Hassman LM, Nikolaidis NM, Rothenberg ME. Persistent effects induced by IL-13 in the lung. Am J Respir Cell Mol Biol 2006; 35: 33746.
  • 25
    Dirks NL, Meibohm B. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 2010; 49: 63359.
  • 26
    Smith DA, Minthorn EA, Beerahee M. Pharmacokinetics and pharmacodynamics of mepolizumab, an anti-interleukin-5 monoclonal antibody. Clin Pharmacokinet 2011; 54: 21527.
  • 27
    Zietkowski Z, Bodzenta-Lukaszyk A, Tomasiak MM, Skiepko R, Szmitkowski M. Comparison of exhaled nitric oxide measurement with conventional tests in steroid-naïve asthma patients. J Investig Allergol Clin Immunol 2006; 16: 23946.
  • 28
    Stirling RG, Kharitonov SA, Campbell D, Robinson DS, Durham SR, Chung KF, Barnes PJ. Exhaled NO is elevated in difficult asthma and correlates with symptoms and disease severity despite treatment with oral and inhaled corticosteroids. Thorax 1998; 53: 10304.
  • 29
    Turner S. Exhaled nitric oxide in the diagnosis and management of asthma. Curr Opin Allergy Clin Immunol 2008; 8: 706.
  • 30
    Suresh V, Mih JD, George SC. Measurement of IL-13-induced i-NOS-derived gas phase nitric oxide in human bronchiole epithelial cells. Am J Respir Cell Mol Biol 2007; 37: 97104.
  • 31
    Chibana K, Trudeau JB, Mustovich AT, Hu H, Zhao J, Balzar S, Chu HW, Wenzel SE. IL-13 induced increases in nitrite levels are primarily driven by increases in inducible nitric oxide synthase as compared with effects on arginases in human primary bronchial epithelial cells. Clin Exp Allergy 2008; 38: 93646.
  • 32
    del Pozo V, de Arruda-Chaves E, de Andres B, Cardaba B, Lopez-Farre A, Gallardo S. Eosinophils transcribe and translate messenger RNA for inducible nitric oxide synthase. J Immunol 1997; 158: 85964.
  • 33
    Matsukura S, Stellato C, Georas SN, Casolaro V, Plitt JR, Miura K, Kurosawa S, Schindler U, Schleimer RP. Interleukin-13 upregulates eotaxin expression in airway epithelial cells by a STAT6-dependent mechanism. Am J Respir Cell Mol Biol 2001; 24: 75561.
  • 34
    Jatakanon A, Kharitonov S, Lim S, Barnes PJ. Effect of differing doses of inhaled budesonide on markers of airway inflammation in patients with mild asthma. Thorax 1999; 54: 10814.
  • 35
    Wenzel S, Wilbraham D, Fuller R, Getz EB. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 2007; 370: 142231.
  • 36
    Corren J, Lemanske RF, Hanania NA, Korenblat PE, Parsey MV, Arron JR. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011; doi: 10.1056/NEJMoa1106469.